A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through ά5Β1 integrin

Blood

Volumn 111, Issue 7, 2008, Pages 3479-3488

  Soro, Simonetta ^a   Orecchia, Angela ^b   Morbidelli, Lucia ^c   Lacal, Pedro Miguel ^b   Morea, Veronica ^a   Ballmer Hofer, Kurt ^d   Ruffini, Federica ^b   Ziche, Marina ^c   D'Atri, Stefania ^b   Zambruno, Giovanna ^b   Tramontane, Anna ^a   Failla, Cristina Maria ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANGIOGENIC PROTEIN; GROWTH FACTOR; IMMUNOGLOBULIN; PEPTIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VERY LATE ACTIVATION ANTIGEN 5; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; CELL ADHESION; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; ANIMAL; CELL MOTION; CHEMISTRY; CYTOLOGY; DRUG EFFECT; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; RABBIT; SIGNAL TRANSDUCTION;

ANGIOGENIC PROTEINS; ANIMALS; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; HUMANS; INTEGRIN ALPHA5BETA1; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RABBITS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 43549106854     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-03-077537     Document Type: Article

References (40)

1. Korpelainen E, Alitalo K. Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol. 1998;10:159-164.
2. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene. 1990;8:519-527.
3. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell. 1997;91:695-704.
4. Christinger HW; Fuh G, de Vos AM, Wiesmann C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem. 2004;279:10382-10388.
5. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor Flt-1. J Biol Chem. 2000;275:26690-26695.
6. Carmeliet P, Moons L. Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathologic conditions. Nat Med. 2001;7:575-583.
7. Sawano A, Iwai S. Sakurai Y, et al. Flt-1, vascular endothelial receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. 2001;97:785-791.
8. Lyden D, Hattori K. Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194-1201.
9. Luttun A. Tjwa M, Moons L. et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt-1. Nat Med. 2002;8:831-840.
10. Fong G, Rossant J, Gertsenstein M, Breitman M. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70.
11. Fong G, Zhang L, Bryce D, Peng J. Increased hemangioblast commitment, not vascular dis-organization, is the primary defect in flt-1 knock-out mice. Development. 1999;126:3015-3025.
12. Hiratsuka S, Minowa O. Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A. 1998;95:9349-9354.
13. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993;90:10705-10709.
14. Inoue T, Kibata K, Suzuki M. Nakamura S. Motoda R, Orita K. Identification of a vascular endothelial growth factor (VEGF) antagonist, sFlt-1, from a human hematopoietic cell line NALM-16. FEBS Lett. 2000;469:14-18.
15. Orecchia A, Lacal PM, Schietroma C, Morea V, Zambruno G, Failla CM. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the α5β1 integrin. J Cell Sci. 2003;116:3479-3489.
16. Francis SE, Goh KL, Hodivala-Dilke K, et al. Central role of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vase Biol. 2002;22:927-933.
17. Kirn S, Bell K, Mausa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am J Pathol. 2000;156:1345-1362.
18. Humphries MJ. Integrin structure. Biochem Soc Trans. 2000;28:311-339.
19. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov. 2003;2:703-716.
20. Leu S. Lam S, Lau L. Pro-angiogenic activities of CYR61 (GCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem. 2002;277:46248-46255.
21. Morbidelli L, Ziche M. The rabbit corneal pocket assay for the study of angiogenesis. Gancer Treat Res. 2004;117:147-151.
22. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28:235-242.
23. Dayringer HE, Tramontano A, Spang SR, Fletterick RJ. Interactive program for visualization and modelling of proteins, nucleic acids and small molecules. J Mol Graph. 1986;4:82-87.
24. Tan DCW, Manjunatha Kini R, Jois SDS, Lim DKF, Xin L, Ge R. A small peptide derived from Fit-1 (VEGFR-1) functions as an angiogenic inhibitor. FEBS Lett. 2001;494:150-156.
25. Yamada KM, Geiger B. Molecular interactions in cell adhesion complexes. Gurr Opin Gell Biol. 1997;9:76-85.
26. Davis-Smyth T, Presta LG, Ferrara N. Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Fit-1 required for binding and structural stability. J Biol Chem. 1998;273:3216-3222.
27. Roskoski RJ. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007;356:323-328.
28. Barberis L, Wary KK, Fiucci G, et al. Distinct roles of the adaptor protein She and focal adhesion kinase in integrin signaling to ERK. J Biol Chem. 2000;275:36532-36540.
29. Eliceri BP. Integrin and growth factor receptor crosstalk. Circ Res. 2001;89:1104-1110.
30. Pillozzi S, Brizzi ME Bernabei PA, et al. VEGFR-1(FLT-1), β1 integrin, and hERG k+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood. 2007;110:1238-1250.
31. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the α5β1 integrin from phage display library. J Biol Chem. 1993;268:20205-20210.
32. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha5 betal integrin from a phage display library. J Cell Biol. 1994;124:373-380.
33. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130:691-703.
34. Wijelath ES, Rahman S, Namekata M, et al. Heparin-ll domain of tibronectin is a vascular endothelial growth factor-binding domain. Circ Res. 2006;99:853-860.
35. Soldi R, Mitola S, Stasly M, Defilippi P, Tarone G, Bussolino F. Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999;18:882-892.
36. Kearney JB. Kappas NC. Ellerstrom C. DiPaola FW, Bautch VL. The VEGF receptor fit-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood. 2004;103:4527-4535.
37. Roberts DM, Kearney JB, Johnson JH, Rosenberg MP, Kumar R, Bautch VL. The VEGF receptor flt-1 (VEGFR-1) modulates flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol. 2004;164:1531-1535.
38. Kong HL, Hecht D, Song W, et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther. 1998;9:823-833.
39. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993-997.
40. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757-1763.